Shots:
- The US FDA has granted 510(k) clearance for EndoTool IV Cloud, a cloud-based patient-specific insulin dosing platform designed for hospitalized pts requiring IV insulin therapy
- Built on the same dosing algorithm as EndoTool IV, the cloud-based platform is designed to support individualized insulin dosing while enabling more scalable implementation, streamlined maintenance, & reduced reliance on on-premise infrastructure for hospitals
- EndoTool IV Cloud is expected to launch commercially in the US before the end of 2026, while existing EndoTool IV users will continue to receive support during the transition to the cloud-based platform
Ref: Businesswire | Image: Glooko | Press Release
Related News: Revvity Receives FDA Clearance for Total Testosterone ChLIA Assay
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
